HOME >> MEDICINE >> NEWS
Researchers seek new hope in old asthma treatment

Theophylline (pronounced theeoffaleen), an asthma medication prescribed since the 1950s, is now being studied for new potential merits. The Effectiveness of Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma or LODO trial is sponsored by the 19 American Lung Association (ALA) Asthma Clinical Research Centers (ACRC) across the country and seeks to enroll over 600 people, age 15 and over, who suffer from persistent asthma symptoms despite treatment. The ALA ACRC at the University of Vermont (UVM), headed by Professor of Medicine and Vermont Lung Center Director Charles Irvin, Ph.D., is the lead study site.

An estimated 26 million Americans have been diagnosed with asthma. About a third of all asthma sufferers are unable to manage their asthma well, Irvin said. The LODO study aims to test its effectiveness as an add-on therapy for this population.

Theophylline is a pill-form asthma treatment classified as a bronchodilator that has been used for over 50 years to help open narrow, inflamed airway passages. The medication became associated with side effects and drug interactions and fell out of favor when newer treatment options became available. Recent studies in such scientific journals as The Lancet and the American Journal of Respiratory Critical Care Medicine suggest that theophylline may have the capacity to reduce airway inflammation and clear away mucus in doses one-quarter to one-third of those needed to open asthmatic passages. So scientists decided to give theophylline another chance.

The LODO study seeks to identify whether or not theophylline can be an effective add-on therapy a booster, so to speak that will produce better overall results for asthmatics. The study will compare the effectiveness and side-effects of low doses of theophylline to montelukast (sold as Singulair), as well as placebo (sugar pill), on asthma patients. During the double-blind study, the patient, the doctor and the research staff
'"/>

Contact: Jennifer Nachbur
jennifer.nachbur@uvm.edu
802-656-7875
University of Vermont
10-May-2002


Page: 1 2

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor Residual ... Innovation to Action Award. , The Innovation to Action Award, a USAID ...
(Date:9/19/2017)... ... 2017 , ... MelaKids, a Laredo-based company, has introduced a new concept for ... Nature gives us a full supply of melanin – in the back of the ... glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown pigment in ...
(Date:9/19/2017)... ... 19, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) , ... in healthcare information exchange and a trusted advisor to the U.S. Department of Health ... entitled Barriers to Adoption of the ERA and EFT Transactions . , ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the ... industry itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. ... natural alkaline water technologies, water filtration systems, and consumer education. ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone ... the first in the U.S. to incorporate magnesium, a critical property for bone ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology:
Cached News: